Skip to main content

Advertisement

Table 2 Anticoagulation effect of rivaroxaban in 24 patients, measured in PPP using different clotting assays

From: Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs

  Peak of activity* in hours Trough of activity** in hours
  (mean ± SD, 2.06 ± 0.29) (mean ± SD, 23.4 ± 1.09)
Ratio R-PT R-aPTT R-TT R-VV R-C R-PT R-aPTT R-TT R-VV R-C
Mean 1.72 1.32 1.15 3.08 3.53 1.20 1.08 1.11 1.66 1.89
SD 0.39 0.16 0.16 0.88 0.68 0.12 0.13 0.11 0.37 0.42
Median 1.61 1.28 1.11 2.75 3.53 1.17 1.03 1.2 1.62 1.97
Highest 2.53 1.74 1.67 5.13 5.63 1.46 1.38 1.26 2.35 2.88
Lowest 1.08 1.1 1.0 1.92 2.24 1.04 0.95 0.9 0.86 0.98
  1. *p < 0.01 for R-VV vs. R-PT, R-aPTT, and R-TT; p < 0.01 for R-C vs. R-PT, R-aPTT, and R-TT.
  2. **p < 0.05 for R-C vs. R-PT, R-aPTT, and RTT; p < 0.05 for R-VV vs. R-PT, R-aPTT, and RTT.